Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score N/A
- Grade Buy
- Symbol (MBII)
- Company Marrone Bio Innovations, Inc.
- Price $0.80
- Changes Percentage (-20.19%)
- Change -$0.2
- Day Low $0.75
- Day High $1.02
- Year High $1.50
Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. It provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Raleigh, North Carolina.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 08/15/2022
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.12
- Trailing P/E Ratio -6.8213675213675
- Forward P/E Ratio -6.8213675213675
- P/E Growth -6.8213675213675
- Net Income $-16,554,000
Income Statement
Quarterly
Annual
Latest News of MBII
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
76ers vs. Grizzlies prediction: Why we're betting on Joel Embiid
The Memphis Grizzlies face the Philadelphia 76ers amid injuries. Despite Grizzlies' resilience, the Sixers struggle with a poor record and Embiid's underperformance. The game could be a turning point ...
By New York Post | 18 hours ago -
76ers star Joel Embiid ripped in team meeting for being late to 'everything': report
The Philadelphia 76ers are facing internal issues after a team meeting was held following a disappointing loss. The meeting addressed the need for stricter coaching and accountability, with star playe...
By Fox News | 1 day ago -
Tyrese Maxey calls out Joel Embiid during Philadelphia 76ers' team meeting after loss to Heat, report says
The Philadelphia 76ers are struggling with a 2-11 record, sparking tension within the team. Tyrese Maxey called out Joel Embiid for lateness, leading to a team meeting for urgency and accountability. ...
By CBS News | 1 day ago
